Description
A CB2 receptor agonist; selective for CB2 over CB1 (Kis = 7.1 and 580 nM); considered a protean agonist because it has neutral antagonist and partial agonist activity, depending on the assay utilized; acts in a species-dependent manner in vitro, acting as an agonist at human CB2 receptors (EC50 = 190 nM) but an inverse agonist at rat and mouse CB2 receptors (EC50s = 216 and 463 nM, respectively); produces antinociception to thermal stimuli in rat hindpaw; neuroprotective, preventing Gp120-induced apoptosis in vitro and increasing survival and differentiation of neural progenitor cells; increases hippocampal neurogenesis in GFAP/Gp120 transgenic mice when administered at a dose of 10 mg/kg daily for ten days; delays motor impairment in a murine model of ALS
Formal name: (2-iodo-5-nitrophenyl)-(1-(1-methylpiperidin-2-ylmethyl)-1H-indol-3-yl)methanone
Synonyms:
Molecular weight: 503.3
CAS: 444912-48-5
Purity: ≥97%
Formulation: A crystalline solid
Application||Product Type|Biochemicals|Receptor Pharmacology|Agonists||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Product Type|Biochemicals|Receptor Pharmacology|Inverse Agonists||Research Area|Neuroscience|Cannabinoid Research|CB1 & CB2 Receptors||Research Area|Neuroscience|Neurodegenerative Disorders||Research Area|Neuroscience|Neuroprotection||Research Area|Neuroscience|Pain Research
